The FDA is recommending that patients continue taking the diabetes medication rosiglitazone, unless told otherwise by their physicians, as the agency continues to look at the risks and benefits of using rosiglitazone to treat type 2 diabetes. Meanwhile, the Senate Committee on Finance and drug manufacturer GlaxoSmithKline, or GSK, are debating the safety of the drug.
Creating memories for families by sharing information relating to children and parents with regard to activities, products, school, home and more.
FDA Offers Docs Guidance on Rosiglitazone as Safety Review Nears Completion
- Login or register to post comments
- Feed: Health of the Public
- Original article